First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28.
Poirier N, Blancho G, Hiance M, Mary C, Van Assche T, Lempoels J, Ramael S, Wang W, Thepenier V, Braudeau C, Salabert N, Josien R, Anderson I, Gourley I, Soulillou JP, Coquoz D, Vanhove B.
Poirier N, et al. Among authors: van assche t.
J Immunol. 2016 Dec 15;197(12):4593-4602. doi: 10.4049/jimmunol.1601538. Epub 2016 Nov 14.
J Immunol. 2016.
PMID: 27849166
Clinical Trial.